Medical marijuana certification for patients with sickle cell disease: a report of a single center experience
Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.Peer-Reviewed Original ResearchConceptsOpioid useMedical marijuanaSickle cell disease (SCD) reportBaseline opioid useSingle-center experienceHealth care utilizationSickle cell diseaseOpioid utilizationClinical characteristicsMost patientsCenter experienceCare utilizationSCD patientsInpatient hospitalizationRandom patientsAdmission ratesCell diseasePatientsRetrospective dataDisease reportsStudy periodHealth careCannabis productsCannabisEdible cannabis productsUrinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use
Koch CD, Xu L, Curtis SA, Roberts JD, Bunch DR, El-Khoury JM. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. Clinica Chimica Acta 2020, 510: 515-521. PMID: 32795544, DOI: 10.1016/j.cca.2020.08.014.Peer-Reviewed Original ResearchConceptsCannabis useUrine samplesLoss of appetiteMinor cannabinoidsRapid LC-MS/MSDronabinol groupDronabinol therapyDronabinol useSevere nauseaPain managementPositive subjectsNormal controlsTherapeutic potentialProspective sampleClinical urine samplesCancer chemotherapySpecific populationsCannabisCannabinoidsMetabolite concentrationsDronabinolLC-MS/MSNegative controlDetection of cannabisCannabidiol